28. January 2015 20:07
Myriad Genetics has essentially given up trying to stop other companies from offering tests for increased risk of breast cancer, ending a dispute that was the subject of a landmark Supreme Court ruling that human genes cannot be patented.
The company has settled or is in the process of se... [More]
18. December 2014 00:54
Myriad Genetics Inc. can’t block competitors’ DNA tests to determine risk for breast and ovarian cancer after a U.S. appeals court said three patents on the tests never should have been issued.
The patents cover products of nature and ideas that aren’t eligible for legal... [More]
11. March 2014 20:53
Myriad Genetics Inc said a U.S. court denied its motion to temporarily stop rival Ambry Genetics Corp from selling products similar to Myriad's gene-based cancer test, the latest setback for the diagnostics company.
Myriad's shares fell 12 percent before the bell on Tuesday.
1. January 2014 20:53
Following the Supreme Court’s rejection of gene patents, the U.S. proposes steep cuts to reimbursements for breast cancer-gene tests.
That natural human genes cannot be patented was one of the biggest biotechnology stories of 2013 and the effects of that Supreme Court decisi... [More]
23. December 2013 17:18
TANIA SIMONCELLI: Gene patent foe
A US science-policy expert fought to keep genes open to all.
In 2005, Tania Simoncelli managed to shock the senior lawyer at the American Civil Liberties Union (ACLU). Simoncelli, the organization’s first science adviser, informed him that companies were s... [More]
10. December 2013 23:17
In the wake of a case that went all the way to the U.S. Supreme Court, Salt Lake City-based Myriad Genetics is now enveloped in a new spate of lawsuits over its gene patents, this time sparring with companies that want to erode its dominant position in testing of genes related to breast and ov... [More]
11. November 2013 21:31
A Federal judge has invalidated the central patent underlying a noninvasive method of detecting Down syndrome in fetuses without the risk of inducing a miscarriage.
The ruling is a blow to Sequenom, a California company that introduced the first such noninvasive test in 2011 and has been t... [More]
9. October 2013 22:51
A controversial new patent for technology that allows people to choose egg and sperm donors, based on the traits they want in their prospective children, is raising questions among experts about the moral bounds of what can be patented.
The U.S. Patent and Trademark Office on Sept. 24... [More]
21. August 2013 22:10
In June the U.S. Supreme Court ruled that patents on genes were invalid. Yet corporate intellectual-property claims can still harm patients.
The court struck down patents held by Myriad Genetics on two human genes linked to breast and ovarian cancers, BRCA1 and BRCA2. The decision ended the c... [More]
23. July 2013 22:40
The National Institutes of Health should use its march-in rights under the Bayh-Dole Act to force Myriad Genetics Inc. to license its patents related to testing for genetic mutations associated with breast and ovarian cancer, according to a July 12 letter sent by Sen. Patrick J. Leahy ... [More]